STOCKHOLM, July 8, 2024
/PRNewswire/ -- SmartCella Holding AB ("SmartCella") today
announces a new share issue raising approximately EUR 50 million to accelerate growth and support
commercialization of the Extroducer and the company's cell and mRNA
operations. The share issue was supported by existing large
institutional investors such as Fjärde AP-fonden, AMF Pension
and SEB-Stiftelsen, as well as a new long-term strategic investor,
AstraZeneca (committing to approximately half of the share issue)
and the new larger institutional investors Handelsbanken Fonder and
RoosGruppen AB, at a pre-money valuation of approximately
EUR 500 million.
SmartCella is a global innovative biotechnology company with a
vision to combine novel delivery platforms, such as the FDA-cleared
Extroducer, with developing cutting-edge cell, and mRNA therapies.
The team consists of global scientists, innovators and visionaries
dedicated to shape the future of targeted medicine through
innovation and solid clinical data with the ambition of making
targeted medicine a reality for many.
The capital raise was supported by existing large institutional
investors Fjärde AP-fonden, AMF Pension, and SEB-Stiftelsen, and
also included new investors such as AstraZeneca, Handelsbanken
Fonder and RoosGruppen AB. Christian
Kinch and Thomas von Koch
remain major shareholders (via SWIB Holding AB). The capital raise
is part of the overall strategic development and future-proofing of
SmartCella which includes continued
investments in the organization and infrastructure as well as
increased commercialization and marketing efforts.
Another strategic building block is the previously announced new
members to the Board of Directors of SmartCella, with Regina Fritsche-Danielson (Senior Vice President
and Global Head of Research and Early Development, Cardiovascular,
Renal and Metabolic Diseases at AstraZeneca), Anna Martling (Professor of Surgery and
Scientific Director Life Science at Karolinska
Institutet) and Claude Dartiguelongue (previously executive
roles with Lonza, Thermo Fisher Scientific and Becton Dickinson and Company).
Christian Kinch, founder and
Chairperson of SmartCella comments: "We are profoundly grateful for
the robust support shown for SmartCella by both our current and new
investors. We have a strong shareholder base, featuring highly
professional investors alongside a science-focused industry and
technology leader like AstraZeneca. The investor endorsement
underscores their confidence in our business model, our team, and
our potential to revolutionize the treatment of some of the most
severe diseases worldwide. SmartCella represents a compelling
investment opportunity with an integrated business model that
blends science, sustainability and impact. SmartCella is truly
about advancing a healthier future."
Niklas Prager, CEO of SmartCella,
says: "We operate in the most exciting and attractive areas of
biotech. Cell and gene therapy are currently the hottest areas in
biotech research and investments, yet SmartCella remains somewhat
of a hidden gem. With the new proceeds, we will continue to build
our organization and drive accelerated growth. We will have a
specific focus on ramping up commercialization of the Extroducer,
which I believe is one of the most groundbreaking innovations in
targeted delivery solutions, carrying therapies directly into
otherwise hard-to-reach tumors or organs. The Extroducer, combined
with our world-class research and knowledge in cell and mRNA
therapies, makes SmartCella unique. This capital raise is a
landmark event for us - and our journey has only just begun."
Regina Fritsche-Danielson, Board
Member of SmartCella adds: "At AstraZeneca, we recognize the
potential of cell and gene therapies to slow, stop and reverse
disease progression in areas where significant unmet need still
exists. I am delighted to join the SmartCella Board of Directors,
building on our existing collaboration with SmartCella and sharing
our knowledge and skills to drive innovation in this rapidly
advancing field."
Skandinaviska Enskilda Banken acted as financial advisor to
SmartCella.
Contact
Niklas Prager,
CEO, +46 76 811 77 44
Nina Nornholm, Head of Corporate Communication, +46 708 550
356
About SmartCella Holding AB
SmartCella, founded in 2014, is a world-leading biotechnology
company pioneering the future of targeted therapies by combining
novel delivery platforms, such as the FDA-cleared Extroducer (an
endovascular device that enables direct infusion to hard-to-reach
organs and tumors), with cutting-edge cell and mRNA therapies. The
team consists of global scientists, innovators and visionaries
dedicated to shape the future of targeted medicine through
innovation and solid clinical data with the ambition of making
targeted medicine a reality for many.
SmartCella operates in two business segments: Targeted
Delivery and Cell/mRNA Therapies.
Read more www.smartcella.com
Follow SmartCella on LinkedIn
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/smartcella-holding-ab/r/smartcella-raises-eur-50-million-to-accelerate-growth-and-commercialization,c4012256
The following files are available for download:
https://mb.cision.com/Main/21365/4012256/2905203.pdf
|
Press release
SmartCella capital raise 240708
|
https://news.cision.com/smartcella-holding-ab/i/smartcella,c3318070
|
smartcella
|
View original
content:https://www.prnewswire.co.uk/news-releases/smartcella-raises-eur-50-million-to-accelerate-growth-and-commercialization-302190580.html